Results 131 to 140 of about 35,440 (172)

New Derivatives of 4-Piperidinylphenyl-Linked Thiazoles as VEGFR2 Inhibitors with Potential Cytotoxicity Against Renal Cancer. [PDF]

Biomolecules
Mahmoud HK, Farghaly TA, Alshareef HF, Alsaedi AMR, Khormi AY, Abdulwahab HG, Abu Alnjaa AM, Hussein SM.   +7 more
europepmc   +1 more source

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. [PDF]

Clin Pharmacokinet
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, Laguna JC, Gorria T, Montes A, Macías I, Alvárez A, Arance A, Moreno FA, Fabregat-Bolufer AB, Soler E, Muner DS.   +15 more
europepmc   +1 more source

Short and Long Non-Coding RNAs in Renal Cell Carcinoma. [PDF]

Noncoding RNA
Cecati M, Pozzi V, Schiavoni V, Barrasso G, Pompei V, Marzioni D, Bonci N, Fumarola S, Ballini A, Sartini D, Campagna R.   +10 more
europepmc   +1 more source

Exploratory Multi-Level Analysis of the HIF Axis in Clear-Cell Renal Cell Carcinoma and Evaluation of GN44028 as an Experimental HIF Pathway-Modulating Compound. [PDF]

Int J Mol Sci
Wierzbicki PM, Rybarczyk A, Czajkowski M, Kieżun J, Kraziński BE, Olszewska A, Kogut-Wierzbicka M, Rudaś Z, Kierczak A, Mitas K, Wrońska L, Grudzińska M, Vital PDS, Kotulak-Chrząszcz A.   +13 more
europepmc   +1 more source

Progressive Destructive Hypothyroidism Associated with Sunitinib Therapy: A Three-Year Case Analysis. [PDF]

J Clin Med
Nosal M.
europepmc   +1 more source

From trial results to bedside decisions: a time-resolved view of CheckMate-9ER. [PDF]

Transl Androl Urol
Fukushima H, Yoshida S, Fujii Y.
europepmc   +1 more source

Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis. [PDF]

BMC Cancer
Di Civita MA, Marinelli D, Michetti VM, Artemi A, Ballario A, Torchia A, Pappalardo L, Pecoraro M, Speranza I, Sciarra A, Panebianco V, Roberto M, Santini D.   +12 more
europepmc   +1 more source

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer. [PDF]

Theranostics
Teisseire M, Karaulic A, Parola J, Totobesola M, Borchiellini D, Pace-Loscos T, Schiappa R, Chamorey E, Durivault J, Dufies M, Ambrosetti D, Luciano F, Gao J, Cao Y, Pagès G, Giuliano S.   +15 more
europepmc   +1 more source

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs. [PDF]

Oncologist
Andrews HS, Agnihotram R, Blumenthal G, Bullock J, Collins G, Doherty GJ, Farago AF, Ishii Y, Kasichayanula S, LeBlanc M, Levi-D'Ancona E, Li C, McCullough K, Morrow PKP, Navarro B, Sandhu P, Shah S, Sharon E, Su Z, Vallett C, Villalobos Y, Allen JD, Stewart MD.   +22 more
europepmc   +1 more source